Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 182 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tetanus Toxoid Vaccine Clear all
Completed Phase 4 Interventional Results available

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women

NCT02783170
View directory record Official record
Conditions
Pregnancy
Interventions
Tetanus, Diphtheria, and Pertussis Vaccine, 2016-2017 Quadrivalent Inactivated Influenza Vaccine, 2017-2018 Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

NCT02752906
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years and older
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
29
States / cities
Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 5, 2026, 5:58 PM EDT
Recruiting Phase 1 Interventional

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

NCT06254326
View directory record Official record
Conditions
Recurrent Oligodendroglioma, Progressive Oligodendroglioma
Interventions
TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 5, 2026, 5:58 PM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898
View directory record Official record
Conditions
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1 Interventional

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies

NCT01846143
View directory record Official record
Conditions
Melanoma
Interventions
pBCAR3-phosphopeptide, pIRS2-phosphopeptide, 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

NCT04056117
View directory record Official record
Conditions
Shigellosis
Interventions
Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
8 Months to 50 Years
Enrollment
597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

NCT01000974
View directory record Official record
Conditions
Haemophilus Influenzae Type b
Interventions
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
63
States / cities
Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cytomegalovirus Vaccine in Healthy Participants

NCT00712634
View directory record Official record
Conditions
Precancerous/Nonmalignant Condition
Interventions
CMVpp65-A*0201 peptide vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2009 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors

NCT05662852
View directory record Official record
Conditions
Tetanus, Diphtheria and Acellular Pertussis Vaccination
Interventions
Tdap
Biological
Lead sponsor
ABO Holdings, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Glassboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 5, 2026, 5:58 PM EDT
Terminated Phase 2 Interventional Results available

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

NCT01339000
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Bladder Cancer
Interventions
Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine, Pneumococcal Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1 Interventional

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer

NCT00892567
View directory record Official record
Conditions
Breast Neoplasms
Interventions
9 Peptides from Her-2/neu, CEA, & CTA
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years · Female only
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

NCT00662870
View directory record Official record
Conditions
Diphtheria, Tetanus, Whooping Cough, Polio, Haemophilus Influenzae Type b
Interventions
DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 84 Days
Enrollment
1,941 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
26
States / cities
Fayetteville, AR 72703, Arkansas • Jonesboro, AR 72401, Arkansas • Little Rock, AR 72211, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

NCT04766086
View directory record Official record
Conditions
Group B Streptococcus Infections
Interventions
Multivalent Group B streptococcus vaccine, Tetanus, diphtheria, and acellular pertussis vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
12
States / cities
Newton, Kansas • Omaha, Nebraska • Las Vegas, Nevada + 8 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

NCT00835237
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
Interventions
Boostrix®, Decavac™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
1,332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • DeLand, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00003224
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
QS21, IFA (incomplete Freund's adjuvant), p946, p946/tet-p, Tet-p
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 5, 2026, 5:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers

NCT00005907
View directory record Official record
Conditions
Active Immunity, Healthy, Stem Cell Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 5, 2026, 5:58 PM EDT
Recruiting Phase 2 Interventional

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT05096481
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NCT02960230
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
K27M peptide, Nivolumab
Biological · Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 5, 2026, 5:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

NCT04843111
View directory record Official record
Conditions
Meningococcal Infection
Interventions
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Swiftwater, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 5, 2026, 5:58 PM EDT